SURMOUNT-1 Results of the first phase 3 obesity trial with the novel GIP/GLP-1 receptor agonist
ADA Presidents' Select Abstract: Effects of Tirzepatide vs. Insulin Glargine 100 U/mL on Kidney Outcomes in Participants with Type 2 Diabetes in SURPASS-4
Dapiglutide, a Once-Weekly GLP-1R/GLP-2R Dual Agonist, Was Safe and Well Tolerated and Showed Dose-Dependent Body Weight Loss over Four Weeks in Healthy Subject
Cardiovascular Effectiveness of Empagliflozin vs. Glucagon-Like Peptide-1 Receptor Agonists or Liraglutide in the EMPRISE Study
Achieving the Unachievable—Will Achievement of Normoglycemia Become a Treatment Goal in T2D?
Expert overviews in other languages